30

Anhui Anke Biotechnology Group Co LtdSHE 300009 Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

1.724

Small

Exchange

XSHE - Shenzhen Stock Exchange

300009.SZ Stock Analysis

30

Attractive

Based on Eyestock quantitative analysis, 300009.SZ`s fundamental data and valuation indicate an investment grade of Attractive at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

107/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

228.4 %

Greatly undervalued

Market cap $B

1.724

Dividend yield

2.55 %

Shares outstanding

1 669.07 B

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the research, development, manufacturing, and sale of biopharmaceutical products. The company is headquartered in Hefei, Anhui and currently employs 2,719 full-time employees. The company went IPO on 2009-10-30. The Company’s main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The firm distributes its products in domestic market and to overseas markets.

View Section: Eyestock Rating